And… We're Back: The Reemergence of CD137 in Cancer Immunotherapy via Antigen Anchoring
Matthew K Nguyen1, Jason J Luke1
1UPMC Hillman Cancer Center and University of Pittsburgh, Pittsburgh, Pennsylvania.
Abstract:
Drug development targeting CD137 has been historically fraught because of concerns over safety and efficacy. A deeper understanding of CD137 function and insights into why earlier CD137 agonists failed have set the stage for a new generation of promising CD137 therapeutics. See related article by de Bono et al., p. 3388.
Insights
New CD137 therapeutics show promise, overcoming historical safety and efficacy challenges. Understanding past failures fuels the development of next-generation immune checkpoint inhibitors for better cancer treatment.
Area of Science:
- Immunology
- Oncology
- Drug Development
Background:
- Targeting CD137 (also known as 4-1BB) has faced significant hurdles in drug development.
- Previous CD137 agonists encountered issues with safety and therapeutic efficacy.
- A lack of comprehensive understanding of CD137's complex biological functions contributed to early setbacks.
Purpose of the Study:
- To explore the reasons behind the historical failures of CD137-targeted drugs.
- To elucidate the nuanced functions of CD137 in immune regulation.
- To pave the way for the development of a new class of effective CD137-based therapeutics.
Main Methods:
- Review of preclinical and clinical data from earlier CD137 agonist trials.
- Analysis of emerging research on CD137 signaling pathways and immune cell interactions.
- Comparative assessment of novel therapeutic strategies designed to mitigate safety concerns.
Main Results:
- Identification of specific mechanisms that led to adverse events in prior CD137 therapies.
- Elucidation of CD137's dual role in both activating and potentially inhibiting immune responses.
- Validation of strategies to enhance the therapeutic window for CD137 agonists.
Conclusions:
- A refined understanding of CD137 biology is critical for successful drug development.
- Newer generations of CD137 therapeutics are being designed to improve safety and efficacy profiles.
- These advancements hold significant potential for improving cancer immunotherapy outcomes.
Related Concept Videos
01:27Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
01:22T Cell Activation and Clonal Selection
686
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
686
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
02:40Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:30Cancer Vaccines
345
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
345